



1624

Practitioner's Docket No. 56476 (71661)
PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Oxford et al.**

Application No.: **09/964,260**

Group No.: **1624**

Filed: **September 26, 2001**

Examiner: **T. N. Truong**

For: **DERIVATIVES OF PYRIMIDO [6,1-A] ISOQUINOLIN-4-ONE**

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

TRANSMITTAL OF CERTIFIED COPIES

Attached please find the certified copies of the foreign applications from which priority is claimed for this case:

Country: **Germany**

Application Number: **9907454.4**

Filing Date: **March 31, 1999**

Country: **Germany**

Application Number: **9909802.2**

Filing Date: **April 28, 1999**

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: **3/3/04**

Lee Dunkle

(type or print name of person mailing paper)

Lee Dunkle

Signature of person mailing paper

1590

1

WARNING: "When a document that is required by statute to be certified must be filed, a copy, including a photocopy or facsimile transmission of the certification is not acceptable." 37 C.F.R. section 1.4(j) (emphasis added).

Date: 3/3/04

Christine C. O'Day

SIGNATURE OF PRACTITIONER

Reg. No.: 38,256

Christine C. O'Day
(type or print name of practitioner)

Edwards & Angell, LLP

Tel. No.: (617) 517-5557


P.O. Box 55874

P.O. Address

Customer No.: 21874

Boston, MA 02205

NOTE: "The claim to priority need be in no special form and may be made by the attorney or agent, if the foreign application is referred to in the oath or declaration, as required by section 1.63." 37 C.F.R. section 1.55(a).





INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *An Brewster*.
Dated 15 January 2004





1/77

01APR99 E436992-1 D00056
P01/7700 0.00 - 9907454.4

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH**Request for grant of a patent**

(See the notes on the back of this form. You can also get
an explanatory leaflet from the Patent Office to help
you fill in this form.)

1. Your reference

RK/P20391GB

2. Patent application number
(The Patent Office will fill in this part)

9907454.4

31 MAR 1999

3. Full name, address and postcode of the or of
each patent applicant (underline all surnames)

VANGUARD MEDICA LIMITED
CHANCELLOR COURT
SURREY RESEARCH PARK
GUILDFORD
SURREY GU2 5SF
GB

65561 61002

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
country/state of its incorporation

GB

4. Title of the invention

COMPOUNDS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

KILBURN & STRODE
20 RED LION STREET
LONDON
WC1R 4PJ

Patents ADP number (if you know it)

125001

6. If you are declaring priority from one or more
earlier patent applications, give the country and
the date of filing of the or each of these earlier
applications and (if you know it) the or each
application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application number

Date of filing
(day / month / year)8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.
See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	:	0
Description	:	36
Claim(s)	:	9
Abstract	:	0
Drawing(s)	:	3

10. If you are also filing any of the following, state how many against each item.

Priority documents	:	-
Translations of priority documents	:	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	:	-
Request for preliminary examination and search (Patents Form 9/77)	:	-
Request for substantive examination (Patents Form 10/77)	:	-
Any other documents (please specify)	:	-

11. I/We request the grant of a patent on the basis of this application.

Signature Date

Kilburn & Strode

Kilburn & Strode 31 March 1999

12. Name and daytime telephone number of person to contact in the United Kingdom

Ms. Rie Kondo
Tel: 0171-539 4200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

COMPOUNDS

The present invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their application as inhibitors of phosphodiesterase (PDE) isoenzymes. More 5 particularly the invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their use in medicine for example as bronchodilators with anti-inflammatory properties.

In all cells where cyclic AMP (cAMP) is present as a secondary messenger, 10 intracellular concentrations of cAMP are regulated by the two processes involved in its formation and degradation. Stimulation of membrane bound receptors on the external surface of the cells (e.g. by β -adrenoceptor agonists) results in activation of adenylyl cyclase to generate cAMP from ATP. Phosphodiesterases present in the cell serve to reduce the concentration of cAMP by hydrolysing it to adenosine monophosphate 15 (AMP).

In a disease such as asthma, the principal cells involved in the associated bronchoconstriction and inflammatory processes are subject to inhibitory control by cAMP. Inhibitors of type III phosphodiesterase raise intracellular levels of cAMP, 20 leading to relaxation of bronchial smooth muscle, whereas inhibitors of type IV phosphodiesterase inhibit the release of damaging mediators from pro-inflammatory cells. Thus, in principle, a combined PDE III/IV inhibitor should have the desirable effects of a β -adrenoceptor agonist plus an inhaled anti-inflammatory steroid which are currently the mainstay of treatment in severe asthma. Moreover, a combined PDE 25 III/IV inhibitor given by inhalation should achieve beneficial effects similar to a β -agonist plus inhaled steroid and should be an unusually effective treatment of asthma and other respiratory disorders without the undesirable glucocorticoid effects of the steroid such as osteoporosis and the stunting of growth.


The potential adverse effects of a PDE III/IV inhibitor (e.g. nausea and vomiting, gastric acid secretion, cardiovascular effects such as increased cardiac contractility, vasodilation and potential arrhythmogenic activity) should be avoidable with a compound that is delivered directly to the lungs by inhalation. It is desirable that the substance is long acting, non irritant and has a taste which is not so unpleasant as to have any adverse effect on patient compliance.

An example of a pyrimido[6,1-a]isoquinolin-4-one derivative with PDE III/IV inhibitory activity and known to possess antihypertensive vasodilator activity is trequinsin (9,10-dimethoxy-3-methyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one), which is described by De Souza *et al.*, *J. Med. Chem.* 27 1470-1480 (1984) and in GB-A-1597717.

As described by De Souza *et al.* and in GB-A-1597717, trequinsin has valuable pharmacological properties, and can be administered to human subjects suffering from, for example, respiratory disorders. However, it is unsuitable for administration by inhalation because of its bitter taste and *in vitro* data indicate its persistence of action is less than desirable.

It has now been found that it is possible to design certain pyrimido[6,1-a]isoquinolin-4-one derivatives which are PDE inhibitors, which have a longer duration of action relative to trequinsin and other useful properties.

According to a first aspect of the present invention there is provided a compound of general formula I:



5 wherein

- each of R¹ and R² independently represents a C₁₋₆ alkyl or C₂₋₇ acyl group;
- R⁵ represents a hydrogen atom or a C₁₋₃ alkyl, C₂₋₃ alkenyl or C₂₋₃ alkynyl group;
- R⁶ represents a hydrogen atom or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, amino, C₁₋₆ alkylamino, di(C₁₋₆) alkylamino or C₂₋₇ acylamino group;
- 10 each of R⁷ and R⁸ independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₇ acyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl; and
- R⁹ represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₇ acyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl group;
- X represents an oxygen atom or a group CR³R⁴, wherein each of R³ and R⁴ independently represents a hydrogen atom or a C₁₋₃ alkyl group;
- 15 each of R¹⁰ and R¹¹ independently represents a hydrogen atom, a C₁₋₃ alkyl, C₃₋₆ cycloalkyl or phenyl group;
- Y represents an oxygen atom or a group CHNO₂, NCN, NH or NNO₂;
- n is an integer from 2 to 4;
- 20 or a salt thereof.

As used herein the term "halogen" or its abbreviation "halo" means fluoro, chloro, bromo or iodo.

- 5 As used herein the term "C₁₋₆ alkyl" refers to straight chain or branched chain alkyl groups having from one to six carbon atoms. Illustrative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, neopentyl and hexyl. C₁₋₄ alkyl groups are preferred.
- 10 As used herein the term "C₂₋₃ alkenyl" refers to straight chain or branched chain hydrocarbon groups having from two to three carbon atoms and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include for example, vinyl and 1-propenyl.
- 15 As used herein the term "C₂₋₃ alkynyl" refers to straight chain hydrocarbon groups having from two to three carbon atoms and having in addition one triple bond. This term would include for example, ethynyl and 1-propynyl.
- 20 As used herein the term "C₂₋₆ alkenyl" refers to straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include for example, vinyl, 1-propenyl, 1- and 2-butenyl and 2-methyl-2-propenyl. C₂₋₃ alkenyl groups are preferred.
- 25 As used herein the term "C₂₋₆ alkynyl" refers to straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1-propynyl, 1- and 2-butynyl, 2-methyl-2-propynyl, 2-pentanyl, 3-pentanyl, 4-pentanyl, 2-hexanyl, 3-hexanyl, 4-hexanyl and 5-hexanyl. C₂₋₃ alkynyl groups are preferred.

As used herein the term "C₁₋₆ alkoxy" refers to straight chain or branched chain alkoxy groups having from one to six carbon atoms. Illustrative of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, *sec*-butoxy, *tert*-butoxy, 5 pentoxy, neopentoxy and hexoxy. C₁₋₄ alkoxy groups are preferred.

As used herein the term "C₂₋₇ acyl" refers to straight chain or branched chain acyl groups having from two to seven carbon atoms. Illustrative of such acyl groups are acetyl, propionyl (or propiono or propanoyl), isopropionyl (or isopropiono or 10 isopropanoyl), butyryl (or butanoyl), isobutyryl (or isobutanoyl), pentanoyl (or valeryl), hexanoyl (or capronyl) and heptanoyl.

As used herein the term "C₂₋₇ acyloxy" refers to straight chain or branched chain acyloxy groups having from two to seven carbon atoms. Illustrative of such acyloxy 15 groups are acetyloxy, propionyl (or propiono or propanoyl)oxy, isopropionyl (or isopropiono or isopropanoyl)oxy, butyryl (or butanoyl)oxy, isobutyryl (or isobutanoyl)oxy, pentanoyl (or valeryl)oxy, hexanoyl (or capronyl)oxy and heptanoyloxy. C₂₋₄ acyloxy groups are preferred.

20 As used herein the term "C₃₋₆ cycloalkyl" refers to an alicyclic group having from three to six carbon atoms. Illustrative of such cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cyclopentyl and cyclohexyl groups are preferred.

25 As used herein the term "C₁₋₆ alkylthio" refers to straight chain or branched chain alkylthio groups having from one to six carbon atoms. Illustrative of such alkylthio groups are methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, *sec*-butylthio, *tert*-butylthio, pentylthio, neopentylthio and hexylthio. C₁₋₄ alkylthio groups are preferred.

As used herein the term "C₁₋₆ alkylamino" refers to straight chain or branched chain alkylamino groups having from one to six carbon atoms. Illustrative of such alkylamino groups are methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, *sec*-butylamino, *tert*-butylamino, pentylamino, neopentylamino and hexylamino. C₁₋₄ alkylamino groups are preferred.

As used herein, the term "di(C₁₋₆) alkylamino" refers to straight chain or branched chain di-alkylamino groups having from one to six carbon atoms in each of the alkyl groups. Illustrative of such dialkylamino groups are di-methylamino, di-ethylamino, di-propylamino, di-isopropylamino, di-butylamino, di-isobutylamino, di-*sec*-butylamino, di-*tert*-butylamino, di-pentylamino, di-neopentylamino and di-hexylamino. Di(C₁₋₄)alkylamino groups are preferred.

As used herein, the term "C₂₋₇ acylamino" refers to straight chain or branched chain acylamino groups having from two to seven carbon atoms. Illustrative of such acylamino groups are acetylamino, propionyl (or propiono or propanoyl)amino, isopropionyl (or isopropiono or isopropanoyl)amino, butyryl (or butanoyl)amino, isobutyryl (or isobutanoyl)amino, pentanoyl (or valeryl)amino, hexanoyl (or capronyl)amino and heptanoylamino. C₂₋₄ acylamino groups are preferred.

Where there is a substituent which renders a compound basic, for example when R⁶ is an amino, alkylamino or dialkylamino group, addition of an acid results in a salt. The acid may be any suitable acid, and can be organic or inorganic.

Preferred compounds of general formula I include those in which, independently or in any compatible combination:

each of R¹ and R² represents a C₁₋₆ alkyl, preferably a C₁₋₄ alkyl, group;

R¹ and R² are the same as each other;
each of R³ and R⁴ represents a hydrogen atom;
R⁵ represents a hydrogen atom;
R⁶ represents a hydrogen atom;
5 each of R⁷ and R⁸ represents a C₁₋₆ alkyl, preferably methyl, ethyl or isopropyl, group;
R⁷ and R⁸ are the same as each other;
R⁹ represents a hydrogen atom, a halogen atom or a methyl or acetyl group;
Y represents an oxygen atom or a group CHNO₂; and
n is 2.

10

Exemplary compounds include:

1. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one;
- 15 2. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-(N'-isopropylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one;
3. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(N'-methyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]-isoquinolin-4-one;
- 20 4. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(N'-isopropyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]-isoquinolin-4-one;
- 25 5. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(N,N'-dimethyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]-isoquinolin-4-one; and

6. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-(N'-phenylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-2-one.

5


The compound: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(*N*-carbamoyl aminoethyl)-3,4,6,7 tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one is particularly preferred.

- 10 Compounds of general formula I may be prepared by any suitable method known in the art and/or by the following process, which itself forms part of the invention.

According to a second aspect of the invention, there is provided a process for preparing a compound of general formula I as defined above, the process comprising:

15

- (a) derivatising a compound of general formula II:



20


II

wherein R¹, R², R⁵, R⁶, R⁷, R⁸, R⁹, X and n are as defined for general formula I, with one or more compounds capable of reacting at the primary amine group of the aminoalkyl moiety $-(\text{CH}_2)_n-\text{NH}_2$, to form a compound of general formula I; or

5

- (b) when X in general formula I represents a group CR³R⁴, wherein R³ represents a hydrogen atom, R⁴ represents a hydrogen atom or a C₁₋₃ alkyl group, and R⁵ represents a hydrogen atom or a C₁₋₃ alkyl group, hydrogenating a compound of general formula III:

10



III

- 15 wherein R¹, R², R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, Y and n are as defined for general formula I; and

- (c) optionally converting a compound of general formula I so formed into another compound of general formula I.

20

The reaction conditions of step (a) are generally such as to favour the reaction, which may be a nucleophilic displacement or addition and is carried out in a solvent which is suitable for the particular reaction.

- 5 Compounds chosen for reacting with a compound of general formula II are capable of reacting at the primary amine group of the alkylamino moiety in the compound of general formula II, to form a compound of general formula I. For example:

when Y represents an oxygen atom and each of R¹⁰ and R¹¹ represents a hydrogen atom, a compound of general formula II may be derivatised with sodium cyanate;

when Y represents an oxygen atom, R¹⁰ represents a hydrogen atom and R¹¹ represents a C₁₋₃ alkyl, C₃₋₆ cycloalkyl or phenyl group, a compound of general formula II may be derivatised with an isocyanate of the general formula R¹¹NCO;

15 when Y represents CHNO₂, R¹⁰ represents a hydrogen atom and R¹¹ represents a C₁₋₃ alkyl or C₃₋₆ cycloalkyl group, a compound of general formula II may be derivatised with an N-C₁₋₃ alkyl- or N-C₃₋₆ cycloalkyl-1-(methylthio)-2-nitroethenamine of the general formula CH₃SC(=CHNO₂)NR¹⁰R¹¹;

20 when Y represents CHNO₂, a compound of general formula II may be reacted first with 1,1-bis(methylthio)-2-nitroethylene and the resulting compound may then be reacted with an amine of the general formula R¹⁰R¹¹NH, wherein R¹⁰ and R¹¹ are as defined for general formula I;

25 when Y represents NH, a compound of general formula II may be derivatised with a compound of general formula CH₃SC(=NH)NR¹⁰R¹¹ or a salt thereof, wherein R¹⁰ and R¹¹ are as defined for general formula I; and

when Y represents NCN, a compound of general formula II may be derivatised with a compound of general formula $\text{CH}_3\text{SC}(=\text{NCN})\text{NR}^{10}\text{R}^{11}$ or a salt thereof, wherein R^{10} and R^{11} are as defined for general formula I.

5 In specific cases:

for 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(*N*-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, sodium cyanate may be chosen;

10

for 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(*N*-isopropylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, isopropylisocyanate may be chosen;

15

for 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(1-(*N*-methyl-2-nitroethenamine))-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, N-methyl-1-(methylthio)-2-nitroethenamine may be chosen;

20


for 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(1-(*N*-isopropyl-2-nitroethenamine))-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, 1,1-bis(methylthio)-2-nitroethylene and isopropylamine may be chosen;

25

for 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(1-(*N,N*-dimethyl-2-nitroethenamine))-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, 1,1-bis(methylthio)-2-nitroethylene and dimethylamine may be chosen; and

for 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(*N*-phenylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-2-one, phenylisocyanate may be chosen.

Compounds of general formula II may be prepared by reacting a compound of general formula IV:




5

IV

wherein R¹, R², R⁵, R⁶, R⁷, R⁸, R⁹ and X are as defined for general formula I, with a compound of general formula V:

10



V


15

wherein n is as defined for general formula I, LG represents a leaving group, and PG represents a protecting group; and then removing the protecting group.

20

The reaction between a compound of general formula IV and a compound of general formula V is generally carried out in suitable conditions for the reaction, which is a nucleophilic substitution. A base such as K₂CO₃ may be used in the presence of NaI and the reaction is performed in a suitable solvent such as 2-butanone.

The leaving group LG in general formula V may be any suitable leaving group, but is preferably a halogen atom, such as bromine. The protecting group PG in general formula V may be any suitable protecting group, such as a phthaloyl group. If the reaction between a compound of general formula IV and V is carried out in a base such as K_2CO_3 , the protecting group should be base-stable. A suitable compound of general formula V is *N*-(2-bromoethyl)phthalimide:




10

The protecting group may then be removed by standard deprotection procedures. For example, hydrazine hydrate may be used. The reaction conditions are generally to favour the reaction, for example in a suitable solvent such as ethanol and/or chloroform at room temperature.

15


Compounds of general formula IV may be prepared by reacting a compound of general formula VI:

20



VI

wherein R¹, R², R⁵, R⁶ and X are as defined for general formula I and LG represents a
 5 leaving group; with a compound of general formula VII:



VII

10

wherein R⁷, R⁸ and R⁹ are as defined for general formula I.

Compounds of general formula VII are substituted anilines which are either known in
 the art and available from commercial sources or may readily be prepared by methods
 15 known *per se*.

The leaving group LG in compounds of general formula VI may be chlorine, a
 thioalkyl group, preferably thiomethyl, or an alkylsulphonyl group, preferably
 methylsulphonyl. Preferably it is chlorine.


20

The reaction conditions are generally such as to favour the reaction, which is a
 nucleophilic displacement which is preferably carried out in a suitable solvent such as
 dimethylformamide or isopropanol in the presence of a base such as potassium
 carbonate. Suitable reaction conditions may be found in GB-A-1597717 and EP-A-
 25 0124893, which disclose the preparation of related compounds.


The reaction is generally applicable for producing compounds of general formula I where R⁶ represents a hydrogen atom or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, amino, C₁₋₆ alkylamino or C₂₋₇ acylamino group and R¹ to R⁵ and R⁷ to R⁹, X, Y and n have the meanings given above.

5

Compounds of general formula VI where LG represents a chlorine atom may be prepared by reacting a compound of general formula VIII or a compound of general formula IX with phosphorous oxychloride, or by heating a compound of general formula VIII with phosphorous pentachloride :



VIII




15

IX

wherein R¹, R², R⁵ and R⁶ and X are as defined for general formula I. Compounds of general formula VI where LG represents a thioalkyl group may be prepared from

compounds of formula VIII by heating with phosphorous pentasulphide in a solvent such as dioxan or pyridine to give initially the intermediate thio derivative of VIII which, on treatment with an alkylating agent such as an alkyl iodide *eg.* methyl iodide, in a suitable solvent such as tetrahydrofuran or ethyl acetate, gives the thioalkyl compound. 5 Oxidation of the thioalkyl compound with, for example, 3-chloroperbenzoic acid in a solvent such as methylene chloride, gives the alkylsulphone derivative.


Compounds of general formula VIII may be prepared by reacting a compound of 10 general formula IX, wherein R¹, R², R⁵ and R⁶ are as defined for general formula I, with a cyclodehydrating agent such as phosphorous oxychloride, under less vigorous condition, *ie* lower temperatures, than those required to give compounds of the general 15 formula VI where LG represents a chlorine atom. An alternative method has been described in NL-A-6,401,827 (Hoffmann-La Roche) which involves reacting the carbamoylmethylene-tetrahydroisoquinoline, general formula XI (wherein R¹, R², R⁵ and X have the meanings given above) with diethyl carbonate in ethanolic sodium ethoxide:



20

XI

Compounds of general formula IX may be prepared by reacting a compound of 20 general formula XII




XII

5

wherein R^1 , R^2 , R^5 and X are as defined for general formula I, with $\text{R}^6\text{CH}(\text{CO}_2\text{Et})_2$, wherein R^6 is as defined for general formula I, and a strong base such as sodium ethoxide in a hot ethanolic solution. Alternatively, the corresponding dimethyl ester can be employed in the presence of hot methanolic sodium methoxide.

10

Compounds of general formula XII may be prepared by reacting a compound of general formula XIII:



15

XIII

wherein R^1 , R^2 , R^5 and X are as defined for general formula I, with urea by heating at 160°C. Alternatively, compounds of general formula XIII may be reacted with potassium cyanate in the presence of acetic acid in a suitable solvent such as ethanol.


20

Compounds of general formula XIII are either known in the art or may readily be prepared by methods known *per se*. For example, the preparation of 1-(3,4-

dimethoxyphenethyl)barbituric acid has been described by B. Lal *et al.* in *J.Med.Chem.* 27 1470-1480 (1984).

Turning to step (b), the reaction conditions of step (b) are generally to favour the hydrogenation reaction, and the reaction is generally carried out in a suitable solvent such as an alcohol; eg ethanol, with a noble metal catalyst such as palladium, platinum, rhodium or nickel, at room temperature. The catalyst may be supported, for example on charcoal or alumina.

- 10 Compounds of general formula III may be prepared from a compound of general formula XIV:



15

XIV

wherein R¹, R² and R⁶ are as defined for general formula I, and R⁴ and R⁵ independently represent a hydrogen atom or a C₁₋₃ alkyl group. The reactions are conducted as described above for converting a compound of general formula VIII to a compound of general formula II through compounds of general formula VI and general formula IV, and the preferred reaction conditions correspond accordingly.

Compounds of general formula XIV may be prepared from compounds of general formula VIII (wherein X represents a CH₂ group and R⁵ represents a hydrogen atom or a C₁₋₃ alkyl group) by heating with a noble metal catalyst such as palladium, platinum, rhodium or nickel at a temperature of 300 to 350°C. The catalyst may be supported on charcoal or alumina and the reaction carried out in an inert solvent such as an aromatic hydrocarbon, *eg* *p*-cymene.

In optional step (c), a compound of general formula I may be converted into another compound of general formula I. For example, compounds of general formula I where R⁶ represents NH₂ may be converted into compounds of general formula I where R⁶ represents a C₁₋₆ alkylamino group by standard chemistry, such as by alkylation of a protected derivative such as an acyl or a *p*-toluenesulphonyl derivative followed by removal of the protecting group, such as by acid hydrolysis. Compounds of general formula I where R⁶ represents a di(C₁₋₆) alkylamino group may be prepared by direct alkylation of the alkylamino derivative. Compounds of general formula I wherein R⁵, R⁶, R⁷, R⁸ and/or R⁹ represent a C₂₋₃ alkenyl, C₂₋₆ alkenyl, C₂₋₃ alkynyl or C₂₋₆ alkynyl group may be hydrogenated to give the corresponding compound with saturated bonds. The reaction conditions for the hydrogenation are as outlined above for step (b).

20

According to a third aspect, the present invention provides a composition comprising a compound of general formula I and a veterinarian or pharmaceutically acceptable carrier or diluent. Preferably the composition is a pharmaceutical composition for human medicine.

25

Compounds of the present invention are PDE inhibitors and thus possess valuable pharmacological properties, such as bronchodilator activity as demonstrated by the inhibition of field-stimulated contraction of guinea-pig isolated trachea, and anti-inflammatory activity as illustrated in studies on human mononuclear cells stimulated

by PHA (phytohaemagglutinin). *In vitro* and *in vivo* data indicate the compounds have a long duration of action, as demonstrated by their persistent protective effects against histamine induced bronchospasm in the guinea-pig when inhaled directly into the lungs as a dry powder. The invention therefore also relates to acute, chronic or prophylactic treatment of patients suffering from respiratory disorders including, in particular, asthma, allergic asthma, hay fever, allergic rhinitis, bronchitis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), and cystic fibrosis. They may also be used topically in skin disorders such as atopic dermatitis and psoriasis, or in ocular inflammation or any other disease including cerebral ischaemia or auto-immune diseases in which increasing intracellular concentrations of cAMP is considered beneficial.

One or more compounds as set out in the first aspect of the invention may be present in association with one or more non-toxic pharmaceutically and/or veterinarily acceptable carriers and/or diluents and/or adjuvants and/or propellants and, if desired, other active ingredients. Suitable carriers or diluents are known in the art (eg *Handbook of Pharmaceutical Excipients* (1994) 2nd Edition, Eds. A. Wade/PJ Weller, The Pharmaceutical Press, American Pharmaceutical Association).

Preferably, the compounds and the compositions of the present invention are administered by inhalation, for example by aerosols or sprays which can disperse the pharmacological active ingredient in the form of a powder or in the form of a solution or suspension. Pharmaceutical compositions with powder-dispersing properties usually contain, in addition to the active ingredient, a liquid propellant with a boiling point below room temperature and, if desired, adjuncts, such as liquid or solid non-ionic or anionic surfactants and/or wetting agent to form a stable dispersion. Pharmaceutical compositions in which the pharmacological active ingredient is in solution contain, in addition to this, a suitable propellant, and furthermore, if necessary, an additional solvent and/or a stabiliser. Instead of the propellant,

compressed air can also be used, it being possible for this to be produced as required by means of a suitable compression and expansion device. Pharmaceutical compositions may also be delivered by breath activated inhalation devices.

- 5 According to a fourth aspect, the present invention provides a compound of general formula I or a composition containing a compound of general formula I for use in medicine.

Compounds of the present invention are useful as inhibitors of phosphodiesterase 10 isoenzymes. The compounds or compositions of the present invention may be used to prevent or treat any disease in which the compounds or compositions are useful, but particularly a disease in which raising the intracellular concentration of cAMP is desirable. Examples of diseases against which compounds are useful include respiratory disorders including, in particular, asthma, bronchitis, chronic obstructive 15 pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), allergic asthma, hay fever, allergic rhinitis, and cystic fibrosis. They may also be used topically in skin disorders such as atopic dermatitis or psoriasis, ocular inflammation, or any other disease including cerebral ischaemia or auto-immune diseases in which increasing intracellular concentrations of cAMP is considered beneficial.

20 This aspect of the invention is particularly relevant to the treatment of humans, but is also applicable to general veterinary industry, in particular domestic animals such as dogs and cats and farm animals such as horses, pigs, cattle, sheep, etc.

25 Dosage levels of the order of about 0.02 mg to about 200mg, to be taken once or twice daily, are useful in the treatment of the above-mentioned conditions. More particularly, a dosage range of about 0.2 mg to about 20 mg, taken once or twice daily, is effective. The particular dosage regime will however ultimately be determined by the attending physician and will take into consideration such factors as the medication

being used, age, weight, severity of symptoms and/or severity of treatment being or to be applied, method of administration of the medication, adverse reactions and/or other contraindications.

- 5 The medication according to this aspect of the invention may be given to a patient together with other active agents, which may for example be a different compound of the present invention, or other compounds. Examples include β_2 -adrenoceptor agonists, topical glucocorticoid steroids, xanthine derivatives, antihistamine compounds, leukotriene antagonists, inhibitors of leukotriene synthesis and/or combinations thereof.

10 According to a fifth aspect, the present invention provides the use of a compound of general formula I in the manufacture of an inhibitor of a type III/IV phosphodiesterase isoenzyme. The invention encompasses the use of a compound of general formula I in the manufacture of a bronchodilator and/or an anti-asthmatic medication and/or a medicament for the prevention or treatment of chronic obstructive pulmonary disease (COPD).

15 The invention also relates to a method for the treatment or prevention of a disease in a mammal where a phosphodiesterase isoenzyme inhibitor and/or a bronchodilator would be expected to be of benefit, which method comprises administering to said mammal an amount of an effective, non-toxic amount of a compound of general formula I. The invention encompasses a method of treating or preventing asthma and/or chronic obstructive pulmonary disease (COPD) in a mammal.

20 25

Preferred features of each aspect of the invention apply to each other aspect of the invention, *mutatis mutandis*.

Figure 1, referred to in Preparations 1 to 4 below, shows the route by which the compounds in Preparations 1 to 4 were synthesised;


5 Figure 2, referred to in Example A below, is a graph showing the effect of 10 μ M of the compound of Example 1 of the present invention on contraction of guinea pig trachea to electrical field stimulation; and over time (n=3), wherein the arrow denotes commencement of washout period; and

10 Figure 3, referred to in Example B below, is a graph showing the effect of the compound of Example 1 of the present invention against proliferation of human mononuclear cells stimulated by PHA, wherein each point represents the mean of six experiments, and vertical lines represent standard error of the mean.

15

Preparation 1: Synthesis of 2-Chloro-6,7-dihydro-9,10-Dimethoxy-4H-pyrimido-[6,1-a]isoquinolin-4-one (shown as (1) in Figure 1)

20



A mixture of 1-(3,4-dimethoxyphenyl) barbituric acid (70g, 0.24mol), prepared according to the method described in B. Lal *et al. J.Med.Chem.* 27 1470-1480 (1984), and phosphorus oxychloride (300ml, 3.22mol) was refluxed for 2.5h. The excess

phosphorous oxychloride was removed by distillation (20mmHg) on warming. After cooling the residue was slurried in dioxan (100ml) and cautiously added to a vigorously stirred ice/water solution (1l). Chloroform (1l) was added and the resulting mixture was basified with 30% sodium hydroxide solution. The organic layer was separated and the aqueous phase further extracted with chloroform (2x750ml). The combined organic extracts were washed with water (1.5l), dried over magnesium sulphate and concentrated in vacuo to leave a gummy material (90g). This was stirred in methanol for a few minutes, filtered and washed with methanol (200ml), diethyl ether (2x200ml) and dried *in vacuo* at 40°C to yield the title compound as a yellow/orange solid. 47g, 62%

(300MHz, CDCl₃) δ 2.96(2H, t, C(7) H₂); 3.96(6H, s, 2xOCH₃; 4.20(2H, t, C(6) H₂); 6.61(1H, s, C(1) H); 6.76(1H, s, Ar-H); 7.10(1H, s, Ar-H).

15 Preparation 2: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (shown as (2) in Figure 1)

2-Chloro-9,10-dimethoxy-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-4-one, prepared according to Preparation 1, (38.5g, 0.13 mol) and 2,4,6-trimethylaniline (52.7g, 0.39 mol) in propan-2-ol (3 l) was stirred and heated at reflux, under nitrogen, for 24h. After cooling to room temperature, the solution was evaporated *in vacuo* and the residue was purified by column chromatography on silica gel, eluting with CH₂Cl₂ / MeOH, initially 98:2, changing to 96:4 once the product began to elute from the column. The title compound was obtained with a slight impurity, (just above the product on tlc). Yield 34.6g, 67%.


Preparation 3: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-N-phthalimidoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one
(shown as (3) in Figure 1)

5 A mixture of 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (which was prepared according to Preparation 2) (60.0g, 0.153 mol), potassium carbonate (191g, 1.38 mol), sodium iodide (137g, 0.92 mol) and *N*-(2-bromoethyl)phthalimide (234g, 0.92 mol) in 2-butanone (1500 ml) was stirred and heated at reflux, under nitrogen, for 4 days. After cooling to room
10 temperature the mixture was filtered and the filtrate was evaporated *in vacuo*. The residue was treated with methanol (1000 ml) and the solid filtered off, washed with methanol and recrystallised from ethyl acetate to obtain the title compound as a pale yellow solid in yield 40.0g, 46%. Evaporation of the mother liquor and column chromatography of the residue on silica gel (CH₂Cl₂ / MeOH 95:5) provided further
15 product 11.7g, 13.5%.

Preparation 4: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (shown as (4) in Figure 1)

20 A mixture of 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-N-phthalimidoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (22.0g, 0.039 mol), prepared according to Preparation 3, and hydrazine hydrate (11.3g, 0.195 mol) in chloroform (300 ml) and ethanol (460 ml) was stirred at room temperature, under nitrogen, for 18h. Further hydrazine hydrate (2.9g, 0.05 mol) was added and the
25 mixture was stirred a further 4h. After cooling in ice / water, the solid was removed by filtration and the filtrate evaporated *in vacuo*. The residue was dissolved in dichloromethane and the insoluble material was removed by filtration. The filtrate was dried (MgSO₄) and evaporated *in vacuo* to afford the title compound as a yellow foam in yield 16.2g, 96%.

Example 1: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one



5

Sodium cyanate (6.0g, 0.092 mol) in water (100 ml) was added dropwise to a stirred solution of 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one, prepared according to Preparation 4 above (20.0g, 0.046 mol) in water (600 ml) and 1N HCl (92 ml) at 80°C. After stirring for 2h at 80°C the mixture was cooled in an ice-bath and basified with 2N NaOH. The mixture was extracted with dichloromethane (3 x 200 ml) and the combined extract was dried (MgSO_4) and evaporated *in vacuo*. The resulting yellow foam was purified by column chromatography on silica gel eluting with CH_2Cl_2 / MeOH (97:3) and triturated with ether to obtain the title compound as a yellow solid, 11.9g, 54%.

15

M.p.: 234-236°C

m/z: $\text{C}_{26}\text{H}_{31}\text{N}_5\text{O}_4$ requires M=477 found (M+1) = 478

HPLC: Area (%) 99.50

Column ODS (150 x 4.6 mm)

20 MP pH3 KH_2PO_4 / CH_3CN (60/40)


FR (ml/min) 1.0

RT (min) 9.25

Detection 250 nm

¹H NMR (300 MHz, CDCl₃): δ 1.92 (1H, br s, NH), 2.06 (6H, s, 2xCH₃), 2.29 (3H, s, CH₃), 2.92 (2H, t, CH₂), 3.53 (2H, m, CH₂), 3.77 (3H, s, OCH₃), 3.91 (3H, s, OCH₃), 4.05 (2H, t, CH₂), 4.40 (2H, t, CH₂), 5.35 (2H, br s, NH₂), 5.45 (1H, s, C=CH), 6.68 (1H, s, ArH), 6.70 (1H, s, ArH), 6.89 (2H, s, 2xArH).

Example 2: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-(N'-isopropylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one



15

Isopropylisocyanate (0.15g, 1.77 mmol) was added dropwise to a stirred solution of 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-aminoethyl)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one (prepared according to Preparation 4 above) (0.7g, 1.61 mmol) in toluene (6 ml) at room temperature, under nitrogen. After 2h the solution was evaporated *in vacuo* and the residue was purified by column


chromatography on silica gel (CH_2Cl_2 / MeOH , 97:3) and triturated with ether to obtain an off-white solid, 0.42g, 50%.

M.p.: 181-182°C
5 m/z: $\text{C}_{29}\text{H}_{37}\text{N}_5\text{O}_4$ requires M=519 found (M+1) = 520
HPLC: Area (%) 94.99
Column ODS (150 x 4.6 mm)
MP pH3 KH_2PO_4 / CH_3CN (40/60)
FR (ml/min) 1.0
10 RT (min) 7.985
Detection 250 nm

^1H NMR (300 MHz, CDCl_3): δ 0.89 (6H, d, 2x CH_3), 2.05 (6H, s, 2x CH_3), 2.29 (3H, s, CH_3), 1.94 (1H, br s, NH), 2.90 (2H, t, CH_2), 3.49 (2H, m, CH_2), 3.77 (3H, s, 15 OCH_3), 3.91 (3H, s, OCH_3), 4.05 (2H, t, CH_2), 4.37 (2H, t, CH_2), 5.02 (1H, br s, NH), 5.46 (1H, s, C=CH), 6.67 (1H, s, ArH), 6.69 (1H, s, ArH), 6.87 (2H, s, 2xArH).

Example 3: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(N'-methyl-2-nitroethenamine)-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]-isoquinolin-4-one

5



10 A mixture of 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-aminoethyl)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, prepared according to Preparation 4 above (0.8g, 1.84 mmol) and *N*-methyl-1-(methylthio)-2-nitroethenamine (0.30g, 2.03 mmol) in toluene (20 ml) was stirred and heated at reflux, under nitrogen, for 2h. After cooling to room temperature the solvent was evaporated *in vacuo* and the residue was purified by column chromatography on silica gel (CH_2Cl_2 / MeOH , 97:3). The title compound was obtained as a yellow foam in yield 0.61g, 62%, which on triturating with ether yielded a yellow solid 0.40g, 41%.

15

M.p.: 126-130°C
 20 m/z: $\text{C}_{28}\text{H}_{34}\text{N}_6\text{O}_5$ requires M=534 found (M+1) = 535
 HPLC: Area (%) 98.98
 Column ODS (150 x 4.6 mm)

MP pH4 KH₂PO₄ / CH₃CN (45/55)

FR (ml/min) 1.0

RT (min) 6.635

Detection 250 nm

5

¹H NMR (300 MHz, CDCl₃): δ 2.07 (6H, s, 2xCH₃), 2.29 (3H, s, CH₃), 2.45 (3H, d, NHCH₃), 2.92 (2H, t, CH₂), 3.65 (2H, m, CH₂), 3.77 (3H, s, OCH₃), 3.90 (3H, s, OCH₃), 4.08 (2H, t, CH₂), 4.32 (2H, m, CH₂), 5.46 (1H, s, =CH), 6.51 (1H, s, CHNO₂), 6.70 (2H, s, 2xArH), 6.90 (2H, s, 2xArH), 8.78 (1H, m, NH), 10.35 (1H, m, NH).

10

15

Example 4: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(N-isopropyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one

1,1-Bis(methylthio)-2-nitroethylene (5.3g, 32.2 mmol) and 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one, prepared according to Preparation 4 above (1.4g, 3.22 mmol) in toluene (20 ml) was stirred and heated at reflux, under nitrogen, for 2h. After cooling to room temperature the solvent was evaporated *in vacuo* and the residue was purified by column chromatography on silica gel (CH₂Cl₂ / MeOH , 99:1). This yielded intermediate compound (shown as compound A below) as an oil which became a light beige solid upon trituration with ether. Yield 0.95g, 53%.


20

Isopropylamine (5 ml) was added to a stirred solution of (A) (0.7g, 1.27 mmol) in dichloromethane (10 ml) and heated at reflux, under nitrogen, for 20h. After cooling, the solution was evaporated *in vacuo* and the residue was purified by column

25

chromatography on silica gel (CH_2Cl_2 / MeOH, 98:2). The title compound (shown as compound B below) was obtained as a foam in yield 0.64g, 89%. This became a pale yellow solid (0.38g) upon trituration with ether.

5



M.p.: 144-146°C

m/z: C₃₀H₃₈N₆O₅ requires M=562 found (M+1) = 563

HPLC: Area (%) 97.57

10 Column ODS (150 x 4.6 mm)

MP pH4 KH₂PO₄ / CH₃CN (40/60)

FR (ml/min) 1.0

RT (min) 9.028


Detection 250 nm

15

¹H NMR (300 MHz, CDCl₃): δ 0.87 (6H, d, CH(CH₃)₂), 2.05 (6H, s, 2xCH₃), 2.29 (3H, s, CH₃), 2.93 (2H, m, CH₂), 3.48 (1H, m CH(CH₃)₂), 3.68 (2H, m, CH₂), 3.78 (3H, s, OCH₃), 3.91 (3H, s, OCH₃), 4.09 (2H, t, CH₂), 4.34 (2H, m, CH₂), 5.48 (1H, s, C=CH), 6.68 (1H, s, CHNO₂), 6.69 (2H, s, 2xArH), 6.90 (2H, s, 2xArH), 7.04 (1H, d, NH), 10.75 (1H, m, NH).

Example 5: 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(N,N-dimethyl-2-nitroethenamine)-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one

5



A solution of compound A shown in Example 4 above (1.0g, 1.81 mmol) and
10 dimethylamine (33% in EtOH, 5.0 ml, 28 mmol) in dichloromethane (10 ml) was stirred at 35°C, under nitrogen, for 18h. The solution was then evaporated *in vacuo* and the residue was purified by column chromatography on silica gel (CH₂Cl₂ / MeOH , 97:3) to obtain the title compound as a yellow foam in yield 0.73g, 73%. This became a pale yellow solid (0.60g) upon trituration with ether.

15

M.p.: 187-189°C

m/z: C₂₉H₃₆N₆O₅ requires M=548 found (M+1) = 549

20 HPLC: Area (%) 97.89

Column ODS (150 x 4.6 mm)

MP pH4 KH₂PO₄ / CH₃CN (45/55)


FR (mL/min) 1.0
 RT (min) 6.768
 Detection 250 nm

5 ^1H NMR (300 MHz, CDCl_3): δ 2.02 (6H, s, $2\times\text{CH}_3$), 2.28 (3H, s, CH_3), 2.95 (2H, m, CH_2), 2.95 (6H, s, $\text{N}(\text{CH}_3)_2$), 3.78 (3H, s, OCH_3), 3.81 (2H, t, CH_2), 3.90 (3H, s, OCH_3), 4.05 (2H, t, CH_2), 4.55 (2H, t, CH_2), 5.43 (1H, s, $\text{C}=\text{CH}$), 6.47 (1H, s, ArH), 6.67 (1H, s, CHNO_2), 6.70 (1H, s, ArH), 6.89 (2H, s, $2\times\text{ArH}$), 9.35 (1H, m, NH).

10

Example 6: **9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-(N'-phenylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-2-one**

15



20 Phenylisocyanate (0.16g, 1.38 mmol) was added dropwise to a stirred solution of 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(2-aminoethyl)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, prepared according to Preparation 4 above (0.6g, 1.38 mmol) in toluene (5 ml) at room temperature, under nitrogen. After 1h the solvent

was evaporated *in vacuo* and the residue was purified by column chromatography on silica gel (CH_2Cl_2 / MeOH, 95:5). After trituration with ether the title compound was obtained as a pale yellow solid 0.61g, 80%.

5 M.p.: 116-118°C

m/z: $\text{C}_{32}\text{H}_{33}\text{N}_5\text{O}_4$ requires M=553 found (M+1) = 554

HPLC: Area (%) 98.80

10 Column ODS (150 x 4.6 mm)

MP 0.02M KH_2PO_4 / CH_3CN (42/58)

FR (ml/min) 0.8

RT (min) 10.622

Detection 254 nm

15

^1H NMR (300 MHz, CDCl_3): δ 2.05 (6H, s, 2x CH_3), 2.30 (3H, s, CH_3), 2.92 (2H, t, CH_2), 3.67 (2H, m, CH_2), 3.78 (3H, s, OCH_3), 3.91 (3H, s, OCH_3), 4.06 (2H, t, CH_2), 4.47 (2H, t, CH_2), 5.51 (1H, s, C=CH), 5.60 (1H, s br, NH), 6.69 (1H, s, ArH), 6.72 (1H, s, ArH), 6.89 (2H, s, 2xArH), 6.90-7.23 (5H, m, 5xArH), 7.62 (1H, br s, NH).

20

The pharmacological utility of the compounds of the present invention has been demonstrated in studies using compounds previously synthesised from the above 25 Examples. The results below serve to illustrate the generic application of the compounds of the present invention.

Example A: Efficacy of a compound of the invention against electrical-induced contraction of guinea-pig isolated trachea

The efficacy of the compound of Example 1, 10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(*N*-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, was tested against electrical-induced contraction of guinea-pig isolated trachea. The results demonstrate that the compound of Example 1 inhibits the contractile responses with a long duration of action.

10 Method

Guinea-pig tracheal rings were suspended in organ baths under 1 g tension between two electrodes and subjected to electrical field stimulation (3Hz, 0.1ms duration and 20V (approx 400mAmps) generated every 100 sec by means of physiological square wave-stimulator. The compound of Example 1 was prepared in Tween 80 (10%) and distilled water (0.01M), which were then added to the organ bath to give a final concentration of 10μM.

15 Results

The result is shown in Figure 2. The compound caused complete inhibition of the contractile response to electrical field stimulation and the relaxation was maintained for 2-4 hours.

Example B: Efficacy of a compound of the invention against proliferation of human mononuclear cells stimulated by PHA

20

The effect of the compound of Example 1, 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(*N*-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one, against proliferation of human mononuclear cells stimulated by PHA was investigated. Proliferation was significantly inhibited by the

compound, indicating that it possesses anti-inflammatory activity. The result below serves to illustrate the generic application of the novel compounds of the present invention.

5 Method

Normal healthy volunteers underwent phlebotomy and 25ml of blood was collected. Mononuclear cells were separated and purified according to the method of Banner *et al.* (Banner *et al. Br. J. Pharmacol.* **116** 3169-3174 (1995)). Human peripheral mononuclear cells (100,000 per well) were stimulated for 24h with phytohaemagglutinin (PHA, 2 μ g/ml) in the absence or presence of the compound of Example 1 (0.001-100 μ M) at 37°C in a 95% air, 5% CO₂ atmosphere. Twenty four hours later, [³H]-thymidine (0.1 μ Ci) was added to each well and the cells were incubated for a further 24h period. Cells were then harvested onto glass fibre filters using a cell harvester (ICN Flow, Buckinghamshire) and counted in a scintillation counter.

10
15

Results

The compound under test caused a concentration dependent inhibition of the proliferation of human mononuclear cells stimulated with PHA (number of experiments is 6; Figure 3). The IC₅₀ values and 95% confidence limits for these compounds are indicated in Table 1. The result is also shown in the graph of Figure 3.


20
25

Table 1: IC₅₀ value for the compound of Example 1 against proliferation of human mononuclear cells stimulated with PHA

Compound from	IC ₅₀	n
Example 1 (554)	0.46 μ M (0.239-0.897)	6

CLAIMS

5 1. A compound of general formula I:



I

10


wherein

- each of R¹ and R² independently represents a C₁₋₆ alkyl or C₂₋₇ acyl group;
- 15 R⁵ represents a hydrogen atom or a C₁₋₃ alkyl, C₂₋₃ alkenyl or C₂₋₃ alkynyl group;
- R⁶ represents a hydrogen atom or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, amino, C₁₋₆ alkylamino, di(C₁₋₆) alkylamino or C₂₋₇ acylamino group;
- 20 each of R⁷ and R⁸ independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₇ acyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl; and
- R⁹ represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₇ acyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl group;

- X represents an oxygen atom or a group CR^3R^4 , wherein each of R^3 and R^4 independently represents a hydrogen atom or a C_{1-3} alkyl group; each of R^{10} and R^{11} independently represents a hydrogen atom, a C_{1-3} alkyl, C_{3-6} cycloalkyl or phenyl group;
- 5 Y represents an oxygen atom or a group CHNO_2 , NCN , NH or NNO_2 ; n is an integer from 2 to 4; or a salt thereof.
- 10 2. A compound of general formula I wherein, independently or in any compatible combination:
- each of R^1 and R^2 represents a C_{1-6} alkyl, preferably a C_{1-4} alkyl, group; R^1 and R^2 are the same as each other; each of R^3 and R^4 represents a hydrogen atom;
- 15 R^5 represents a hydrogen atom; R^6 represents a hydrogen atom; each of R^7 and R^8 represents a C_{1-6} alkyl, preferably methyl, ethyl or isopropyl, group; R^7 and R^8 are the same as each other; R^9 represents a halogen atom or a methyl or acetyl group;
- 20 Y represents an oxygen atom or a group CHNO_2 ; and n is 2.
- 25 3. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(*N*-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.
4. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(*N*'-isopropylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

5. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(*N*¹-methyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.
- 5 6. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(*N*¹-isopropyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.
- 10 7. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(*N,N*-dimethyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.
- 15 8. 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-(*N*¹-phenylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-2-one.
- 20 9. A process for preparing a compound of general formula I as defined in claim 1, the process comprising:


(a) derivatising a compound of general formula II:



II

5 wherein R¹, R², R⁵, R⁶, R⁷, R⁸, R⁹, X and n are as defined for general formula I, with one or more compounds capable of reacting at the primary amine group of the aminoalkyl moiety -(CH₂)_n-NH₂, to form a compound of general formula I; or

10 (b) when X in general formula I represents a group CR³R⁴, wherein R³ represents a hydrogen atom, R⁴ represents a hydrogen atom or a C₁₋₃ alkyl group, and R⁵ represents a hydrogen atom or a C₁₋₃ alkyl group, hydrogenating a compound of general formula III:



15

III

wherein R¹, R², R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, Y and n are as defined for general formula I; and

20

- (c) optionally converting a compound of general formula I so formed into another compound of general formula I.
10. A process as claimed in claim 9, wherein in general formula I, when Y represents an oxygen atom and each of R¹⁰ and R¹¹ represents a hydrogen atom, a compound of general formula II is derivatised with sodium cyanate.
11. A process as claimed in claim 9, wherein in general formula I, when Y represents an oxygen atom, R¹⁰ represents a hydrogen atom and R¹¹ represents a C₁₋₃ alkyl, C₃₋₆ cycloalkyl or phenyl group, a compound of general formula II is derivatised with an isocyanate of the general formula R¹¹NCO.
12. A process as claimed in claim 11, wherein the isocyanate is isopropylisocyanate or phenylisocyanate.
15. A process as claimed in claim 9, wherein in general formula I, when Y represents CHNO₂, R¹⁰ represents a hydrogen atom and R¹¹ represents a C₁₋₃ alkyl or C₃₋₆ cycloalkyl group, a compound of general formula II is derivatised with an N-C₁₋₃ alkyl- or N-C₃₋₆ cycloalkyl-1-(methylthio)-2-nitroethenamine of the general formula CH₃SC(=CHNO₂)NR¹⁰R¹¹.
14. A process as claimed in claim 13, wherein the compound of general formula II is derivatised with N-methyl-1-(methylthio)-2-nitroethenamine.
25. 15. A process as claimed in claim 9, wherein in general formula I, when Y represents CHNO₂, a compound of general formula II is reacted first with 1,1-bis(methylthio)-2-nitroethylene and the resulting compound is then reacted with an amine of the general formula R¹⁰R¹¹NH, wherein R¹⁰ and R¹¹ are as defined for general formula I.

16. A process as claimed in claim 15, wherein the amine is isopropylamine or dimethylamine.
5. 17. A process as claimed in claim 9, wherein when in general formula I, Y represents NH, a compound of general formula II is derivatised with a compound of general formula $\text{CH}_3\text{SC}(=\text{NH})\text{NR}^{10}\text{R}^{11}$ or a salt thereof, wherein R^{10} and R^{11} are as defined for general formula I.
10. 18. A process as claimed in claim 9, wherein when in general formula I, Y represents NCN, a compound of general formula II is derivatised with a compound of general formula $\text{CH}_3\text{SC}(=\text{NCN})\text{NR}^{10}\text{R}^{11}$ or a salt thereof, wherein R^{10} and R^{11} are as defined for general formula I.
15. 19. A process as claimed in any of claims 9 to 18, wherein the compound of general formula I is as defined in any of claim 1 to 8.
20. 20. A composition comprising a compound of general formula I and a veterinarily or pharmaceutically acceptable carrier or diluent.
20. 21. A composition as claimed in claim 20, further comprising an active agent such as a β_2 -adrenoceptor agonist or a glucocorticoid steroid.
25. 22. A composition as claimed in claim 20 or claim 21, wherein the composition is a pharmaceutical composition for human medicine.
23. A composition as claimed in claim 20, 21 or 22, adapted for administration by aerosol.


24. A composition as claimed in any of claims 20 to 23, wherein the compound is as defined in any of claims 1 to 8.
- 5
25. A compound of general formula I for use in medicine.
- 10
26. A compound of general formula I for use as an inhibitor of a phosphodiesterase isoenzyme.
27. A compound of general formula I for use in the prevention or treatment of a disease in which raising the intracellular concentration of cAMP is desirable.
- 15
28. A compound of general formula I for use in the prevention or treatment of asthma.
29. A compound of general formula I for use in the prevention or treatment of chronic obstructive pulmonary disease (COPD).
30. A compound as claimed in any of claims 25 to 29, wherein the compound is as defined in any of claims 1 to 8.
- 20
31. The use of a compound of general formula I in the manufacture of an inhibitor of a type III/IV phosphodiesterase isoenzyme.
32. The use of a compound of general formula I in the manufacture of a bronchodilator.
- 25
33. The use of a compound of general formula I in the manufacture of an anti-asthmatic.

34. The use of a compound of general formula I in the manufacture of a medicament for the prevention or treatment of chronic obstructive pulmonary disease (COPD).
- 5 35. The use as claimed in any of claims 31 to 34, wherein the compound is as defined in any of claims 1 to 8.
- 10 36. A method for the treatment or prevention of a disease in a mammal where a phosphodiesterase isoenzyme inhibitor and/or a bronchodilator would be expected to be of benefit, which method comprises administering to said mammal an effective, non-toxic amount of a compound of general formula I.
- 15 37. A method for the treatment or prevention of asthma in a mammal, which method comprises administering to said mammal an effective, non-toxic amount of a compound of general formula I.
- 20 38. A method for the treatment or prevention of chronic obstructive pulmonary disease (COPD) in a mammal, which method comprises administering to said mammal an effective, non-toxic amount of a compound of general formula I.
- 25 39. A method as claimed in claim 36, 37 or 38, wherein the compound is as defined in any of claims 1 to 8.
40. A method as claimed in any of claims 36 to 39, wherein the compound is administered by aerosol.
41. A method as claimed in any of claims 36 to 40, wherein the animal is a human.
42. A compound substantially as hereinbefore described in any of the examples.

43. A process substantially as hereinbefore described in any of the examples.



Figure 1








Figure 2

The effect of the compound of Example 1 ($10\mu M$) on contraction of guinea pig trachea to electrical field stimulation over time ($n=3$). Arrow denotes commencement of washout period.






Figure 3

Effect of the compound of Example 1 against proliferation of human mononuclear cells stimulated by PHA. Each point represents the mean of six subjects, and vertical lines represent standard error of the mean.



Compound of Example 1

